Who it's for
Adults already inside the protocol — on the peptide, mid-taper, mid-cycle, or working an anchor daily — who want structured coaching, not a course. Founders, operators, clinicians, athletes, and knowledge workers whose capacity to stay regulated is the whole job.
How it works
You book, complete the coaching onboarding, and land on a first 1:1 within seven days. Between sessions, weekly check-ins flag drift (sleep debt, HRV drop, protein floor missed, cortisol curve inverted) and route it to the next call. Cancel any time; keep your purchased Anchors.
What the evidence actually supports
Evidence reviewed: 2026-11-16
BPC-157
Still the most-searched non-weight-loss peptide, and still without a published randomised human trial. Rodent repair signals, a 2025 IV safety pilot in two adults and a retrospective knee series do not establish efficacy or long-term safety. FDA's July 2026 briefing concluded the human safety and effectiveness evidence was insufficient; the October 2026 US compounding policy changed access, not that conclusion.
No validated routine human dose, injection location, cycle or BPC-157/TB-500 combination is established. Keep rehabilitation, sleep and nutrition separate from experimental-drug claims. A purity certificate does not establish clinical safety.
TB-500
TB-500 is marketed as a thymosin beta-4 fragment. Studies of full-length thymosin beta-4 cannot be borrowed as proof that the fragment heals human injuries. FDA's 2026 briefing found fragment-specific human evidence insufficient; inclusion in the US compounding policy is not a demonstration that it works.
No established human recovery regimen or proven BPC-157 combination. Competitive athletes must check anti-doping rules; thymosin beta-4 and derivatives including TB-500 are prohibited at all times.
GHK-Cu
Topical copper-peptide cosmetics and injectable GHK-Cu are different evidence questions. Limited topical studies do not establish systemic repair or lifespan extension. GHK-Cu was the fastest-rising peptide search of 2026, but injectable nominations were withdrawn and FDA says it will consult its compounding committee on non-injectable GHK-Cu before the end of February 2027.
Use cosmetic products according to their own instructions; do not extrapolate their results to injections. No validated injectable anti-ageing regimen. Skin symptoms still need dermatological assessment when persistent.
2026: easier US access is not new evidence
In April 2026 FDA took BPC-157, TB-500, Semax, Selank, MOTS-c, KPV, Epitalon, CJC-1295, AOD-9604, LL-37 and others off its Category 2 safety-risk list after their nominations were withdrawn. In July its compounding advisory committee narrowly recommended six of them for the 503A bulks list, over the objection of FDA's own drug reviewers, who found insufficient human safety and effectiveness evidence. On 30 October 2026 HHS published an interim policy: it will not act against US pharmacies compounding BPC-157, TB-500, MOTS-c, Epitalon, Semax or KPV if ten conditions are met.
That is an enforcement posture, not an FDA approval, a bulks-list rule or a clinical trial. It excludes 'research use only' vials and does not travel to Portugal, the UK or the EU, where a product presented or acting as a medicine still needs a marketing authorisation. Better sourcing lowers one risk, contamination, and leaves the efficacy question precisely where it was.